MMJ finds support for Australia push

Published at Apr 20, 2016, in Biotech

MMJ PhytoTech (ASX:MMJ) has taken the next step towards being an established medical cannabis player in Australia, clinching two partnerships to help facilitate the move – focused on lobbying and setting up a retail network.

MMJ told its shareholders in a note this morning that it had signed two letters of intent, with Fresh Therapeutics Compounding Pharmacy and Epilepsy Action Australia respectively.

The former will be aimed at developing a model to import and sell MMJ’s existing products, which are legal under the current regulatory environment.

The deal will initially centre around MMJ’s Gelpell gastro-resistant microgel cannabidiol oral capsules.

Developed as a dietary supplement initially for the European market, phase one trials indicated that there was higher bioavailability of the drug’s active ingredients against an oral spray developed by GW Pharmaceuticals.

MMJ said the deal, should it come to full fruition, would generate immediate cashflow within the current regulatory framework while setting up a sales network should legislation change around MMJ’s other medicinal cannabis products.

Elsewhere, it will have a partner on the lobbying front – with it signing a letter of intent with Epilepsy Action Australia.

While MMJ said it would continue to lobby on its own, it would work with the body to advance the availability, access, and acceptance of medicinal cannabis in Australia through research, advocacy, and education.

Epilepsy Action Australia CEO Carol Ireland said MMJ and the body had identical goals – mainly increasing the availability of effective treatment options for those suffering from epilepsy.

“Given the enormous potential of medicinal cannabis treatment options for people with epilepsy, we are delighted to partner with a company as progressive as MMJ,” she said.

“Their pioneering work in alternative delivery systems of medical cannabis is a logical fit for us and we are looking forward to collaborating and progress the development of effective treatments in a space where they are currently so limited.”

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Facebook
Twitter
LinkedIn